Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brepocitinib tosylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brepocitinib tosylate overview

Brepocitinib tosylate is under development for the treatment of moderate to severe hidradenitis suppurativa, systemic lupus erythematosus, dermatomyositis, non-infectious uveitis, posterior uveitis, panuveitis, intermediate uveitis. It is administered through the oral route as a tablet and by topical route as cream. It acts by targeting both JAK1 and TYK2 protein kinases.

It was also under development for the treatment of plaque psoriasis, mild to moderate atopic dermatitis (AD), Crohn's disease, psoriatic arthritis, cicatricial alopecia (CA), psoriasis, active non-segmental vitiligo and moderate to severe ulcerative colitis.

Priovant Therapeutics overview

Priovant Therapeutics is dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant Therapeutics is headquartered in New York City, New York, the US.

For a complete picture of Brepocitinib tosylate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.